ThaiPR.NET https://www.thaipr.net/location/darmstadt-germany Press Release Distribution Center of Thailand Mon, 20 Apr 2026 17:36:49 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven Experimentation Planner]]> https://www.thaipr.net/en/health_en/3420063 Thu, 07 Dec 2023 08:33:13 +0700 health_en https://www.thaipr.net/en/health_en/3420063 Merck, a leading science and technology company, and the Acceleration Consortium, based at the University of Toronto, Canada, today jointly announced that their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on GitHub, with an unrestricted Apache 2.0 license. The joint open-source initiative combines the Merck portfolio of use cases with the Acceleration Consortium’s world-leading […]

The post Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven Experimentation Planner appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis]]> https://www.thaipr.net/en/it_en/3419251 Wed, 06 Dec 2023 08:05:00 +0700 it_en https://www.thaipr.net/en/it_en/3419251 Merck, a leading science and technology company, today launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through SynthiaTM retrosynthesis software application programing interface (API) integration. It combines generative AI, machine learning and computer-aided drug-design to speed up drug development. Trained on more than two decades of […]

The post Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform]]> https://www.thaipr.net/en/it_en/3222825 Wed, 10 Aug 2022 08:00:00 +0700 it_en https://www.thaipr.net/en/it_en/3222825 Reduces process development time by an estimated 40 percent Enables biopharmaceutical companies to increase the speed to clinical manufacturing Adds to company’s best-in-class VirusExpress® Lentiviral Production Platform Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral […]

The post Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies]]> https://www.thaipr.net/en/health_en/3205823 Fri, 24 Jun 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3205823 Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs) Merck now one of industry’s largest manufacturers of these components globally Builds on company’s 30 years’ CDMO experience with multi-step, complex, and highly potent compounds Merck, a leading science and technology company, announced that its Life Science business sector has doubled its high-potent […]

The post Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies]]> https://www.thaipr.net/en/it_en/3115172 Fri, 29 Oct 2021 08:10:00 +0700 it_en https://www.thaipr.net/en/it_en/3115172 – Merck’s unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges  – New DOLCORE™ platform increases speed-to-market by up to a year – Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company’s 15 years of ADC Contract Development Manufacturing Organization (CDMO) experience – Reinforces company’s ambition to accelerate growth in “Big Three” businesses, […]

The post Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy]]> https://www.thaipr.net/en/it_en/3108924 Thu, 14 Oct 2021 08:00:00 +0700 it_en https://www.thaipr.net/en/it_en/3108924 Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors Investment serves customers in addressing larger patient populations with new curative treatments Enables suspension production of viral vectors up to 1,000-liter scale Project adds to company’s ambition to accelerate growth through investments in “Big 3” businesses, which includes plans […]

The post Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Accelerates Scale Up of Lipids to Meet Covid-19 Demand]]> https://www.thaipr.net/en/it_en/3058408 Thu, 27 May 2021 08:15:00 +0700 it_en https://www.thaipr.net/en/it_en/3058408 – Introduces new synthetic cholesterol product nine months ahead of schedule – Offers high purity, scalability, and consistent quality – One of a few companies that produces lipids in quantities needed to meet demand for mRNA therapeutics, including Pfizer-BioNTech Covid-19 Vaccine   To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, Merck, a […]

The post Merck Accelerates Scale Up of Lipids to Meet Covid-19 Demand appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies]]> https://www.thaipr.net/en/it_en/3039062 Thu, 18 Mar 2021 08:10:00 +0700 it_en https://www.thaipr.net/en/it_en/3039062 – € 25 million investment in Molsheim, France, will create 350 new jobs – Response to unprecedented global demand of key technology – Production capabilities anticipated to be operational by end of 2021 Merck, a leading science and technology company, will add a single-use assembly production unit at its Life Science Center in Molsheim, France. […]

The post Merck Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer]]> https://www.thaipr.net/en/health_en/3038403 Tue, 16 Mar 2021 14:10:12 +0700 health_en https://www.thaipr.net/en/health_en/3038403 Not intended for US-, Canada- or UK-based media Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of […]

The post Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer appeared first on ThaiPR.NET.

]]> <![CDATA[New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines]]> https://www.thaipr.net/en/health_en/3033009 Mon, 01 Mar 2021 08:08:57 +0700 health_en https://www.thaipr.net/en/health_en/3033009 MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine sub-study show protective influenza antibody levels at four weeks post-vaccination in MS patients taking MAVENCLAD In both studies, protective antibody […]

The post New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics]]> https://www.thaipr.net/en/health_en/3016848 Thu, 07 Jan 2021 16:15:19 +0700 health_en https://www.thaipr.net/en/health_en/3016848 – Adds to Merck’s lipid manufacturing expertise, providing an integrated offering across mRNA value chain – AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing – Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing Merck portfolio Merck, a […]

The post Merck Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics appeared first on ThaiPR.NET.

]]> <![CDATA[Merck Expands Life Science Production Capacities in the United States]]> https://www.thaipr.net/en/it_en/3007957 Tue, 08 Dec 2020 09:41:43 +0700 it_en https://www.thaipr.net/en/it_en/3007957 – Expansions to significantly increase capacity by end of 2021 to meet unprecedented demand – Combined expansion of Danvers, Massachusetts, and Jaffrey, New Hampshire, USA facilities to create nearly 700 new positions – Business sector’s announced 2020 investments total more than € 350 million Merck, a leading science and technology company, today announced the broadening […]

The post Merck Expands Life Science Production Capacities in the United States appeared first on ThaiPR.NET.

]]> <![CDATA[European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations]]> https://www.thaipr.net/en/health_en/3005082 Fri, 27 Nov 2020 08:30:43 +0700 health_en https://www.thaipr.net/en/health_en/3005082 Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations. With this validation, the application is complete, and […]

The post European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations appeared first on ThaiPR.NET.

]]>